1. Home
  2. ADVM vs CPHC Comparison

ADVM vs CPHC Comparison

Compare ADVM & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • CPHC
  • Stock Information
  • Founded
  • ADVM 2006
  • CPHC 1994
  • Country
  • ADVM United States
  • CPHC United States
  • Employees
  • ADVM N/A
  • CPHC N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • CPHC Services-Misc. Amusement & Recreation
  • Sector
  • ADVM Health Care
  • CPHC Consumer Discretionary
  • Exchange
  • ADVM Nasdaq
  • CPHC Nasdaq
  • Market Cap
  • ADVM 94.6M
  • CPHC 92.5M
  • IPO Year
  • ADVM 2014
  • CPHC 1994
  • Fundamental
  • Price
  • ADVM $4.48
  • CPHC $16.60
  • Analyst Decision
  • ADVM Strong Buy
  • CPHC
  • Analyst Count
  • ADVM 4
  • CPHC 0
  • Target Price
  • ADVM $19.75
  • CPHC N/A
  • AVG Volume (30 Days)
  • ADVM 800.9K
  • CPHC 2.0K
  • Earning Date
  • ADVM 11-03-2025
  • CPHC 11-06-2025
  • Dividend Yield
  • ADVM N/A
  • CPHC 1.70%
  • EPS Growth
  • ADVM N/A
  • CPHC N/A
  • EPS
  • ADVM N/A
  • CPHC 0.03
  • Revenue
  • ADVM $1,000,000.00
  • CPHC $60,069,270.00
  • Revenue This Year
  • ADVM $1,449.40
  • CPHC N/A
  • Revenue Next Year
  • ADVM N/A
  • CPHC N/A
  • P/E Ratio
  • ADVM N/A
  • CPHC $558.56
  • Revenue Growth
  • ADVM N/A
  • CPHC N/A
  • 52 Week Low
  • ADVM $1.78
  • CPHC $15.91
  • 52 Week High
  • ADVM $8.56
  • CPHC $22.93
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 53.05
  • CPHC 46.43
  • Support Level
  • ADVM $4.11
  • CPHC $16.40
  • Resistance Level
  • ADVM $5.59
  • CPHC $16.94
  • Average True Range (ATR)
  • ADVM 0.52
  • CPHC 0.45
  • MACD
  • ADVM -0.09
  • CPHC 0.07
  • Stochastic Oscillator
  • ADVM 27.75
  • CPHC 36.45

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About CPHC Canterbury Park Holding Corporation 'New'

Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.

Share on Social Networks: